Impact of immunosuppression on incidence of post-transplant diabetes mellitus in solid organ transplant recipients: Systematic review and meta-analysis

Figure 3 Estimates and 95% confidence intervals from the network meta-analysis comparing the odds of developing post-transplant diabetes mellitus in patients receiving tacrolimus or sirolimus compared to the odds with cyclosporine as the mainstay of treatment. The “All” estimate uses the first time-point from each study. The other estimates are presented according to the timing of that post-transplant diabetes mellitus assessment.